

CELGENE CORP /DE/  
Form 8-K  
August 23, 2012

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE**  
**SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): August 21, 2012

**CELGENE CORPORATION**

(Exact name of registrant as specified in its charter)

Delaware  
(State or other jurisdiction of  
incorporation)

001-34912  
(Commission File Number)

22-2711928  
(IRS Employer Identification No.)

86 Morris Avenue, Summit, New Jersey  
(Address of principal executive offices)

07901  
(Zip Code)

Edgar Filing: CELGENE CORP /DE/ - Form 8-K

Registrant's telephone number, including area code: (908) 673-9000

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**ITEM 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.**

On August 21, 2012, Celgene Corporation (the Company ) announced that, effective September 1, 2012, Graham Burton, MBBS, FRCP, will relinquish his responsibilities as Senior Vice President Global Regulatory Affairs, Pharmacovigilance, Corporate Quality and Compliance. In his transition to retirement, Dr. Burton will take on new assignments that capitalize on his extensive global expertise and worldwide stakeholder relationships.

**SIGNATURES**

Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**CELGENE CORPORATION**

Date: August 23, 2012

By: /s/ Jacquelyn A. Fouse

Jacquelyn A. Fouse  
Executive Vice President and  
Chief Financial Officer